Literature DB >> 30523718

Using Gene Expression Profiling to Move Beyond MYC/BCL2 Rearrangements in High-Grade Lymphoma.

Wing C Chan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30523718      PMCID： PMC6338390          DOI： 10.1200/JCO.18.01910

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  30 in total

1.  Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.

Authors:  Ken H Young; Dennis D Weisenburger; Bhavana J Dave; Lynette Smith; Warren Sanger; Javeed Iqbal; Elias Campo; Jan Delabie; Randy D Gascoyne; German Ott; Lisa Rimsza; H Konrad Müller-Hermelink; Elaine S Jaffe; Andreas Rosenwald; Louis M Staudt; Wing C Chan; Timothy C Greiner
Journal:  Blood       Date:  2007-09-19       Impact factor: 22.113

2.  P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.

Authors:  Xuan J Wang; Carlos E Bueso-Ramos; Guilin Tang; Sa Wang; Yasuhiro Oki; Parth Desai; Joseph D Khoury; Roberto N Miranda; Zhenya Tang; Nishitha Reddy; Shaoying Li
Journal:  Mod Pathol       Date:  2016-10-14       Impact factor: 7.842

3.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

4.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.

Authors:  Kerry J Savage; Nathalie A Johnson; Susana Ben-Neriah; Joseph M Connors; Laurie H Sehn; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne
Journal:  Blood       Date:  2009-08-24       Impact factor: 22.113

5.  CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

Authors:  Shimin Hu; Zijun Y Xu-Monette; Aarthi Balasubramanyam; Ganiraju C Manyam; Carlo Visco; Alexander Tzankov; Wei-min Liu; Roberto N Miranda; Li Zhang; Santiago Montes-Moreno; Karen Dybkær; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Xiaoying Zhao; Jane N Winter; Mingzhi Zhang; Ling Li; Michael B Møller; Miguel A Piris; Yong Li; Ronald S Go; Lin Wu; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-01-23       Impact factor: 22.113

6.  An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.

Authors:  Zheng Zhou; Laurie H Sehn; Alfred W Rademaker; Leo I Gordon; Ann S Lacasce; Allison Crosby-Thompson; Ann Vanderplas; Andrew D Zelenetz; Gregory A Abel; Maria A Rodriguez; Auayporn Nademanee; Mark S Kaminski; Myron S Czuczman; Michael Millenson; Joyce Niland; Randy D Gascoyne; Joseph M Connors; Jonathan W Friedberg; Jane N Winter
Journal:  Blood       Date:  2013-11-21       Impact factor: 22.113

7.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.

Authors:  Zijun Y Xu-Monette; Lin Wu; Carlo Visco; Yu Chuan Tai; Alexander Tzankov; Wei-min Liu; Santiago Montes-Moreno; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; X Frank Zhao; William W L Choi; Xiaoying Zhao; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Fan Zhou; Brad S Kahl; Jane N Winter; Wei Xu; Jianyong Li; Ronald S Go; Yong Li; Miguel A Piris; Michael B Møller; Roberto N Miranda; Lynne V Abruzzo; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

8.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Authors:  Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Atanas Kamburov; Robert A Redd; Mike S Lawrence; Margaretha G M Roemer; Amy J Li; Marita Ziepert; Annette M Staiger; Jeremiah A Wala; Matthew D Ducar; Ignaty Leshchiner; Ester Rheinbay; Amaro Taylor-Weiner; Caroline A Coughlin; Julian M Hess; Chandra S Pedamallu; Dimitri Livitz; Daniel Rosebrock; Mara Rosenberg; Adam A Tracy; Heike Horn; Paul van Hummelen; Andrew L Feldman; Brian K Link; Anne J Novak; James R Cerhan; Thomas M Habermann; Reiner Siebert; Andreas Rosenwald; Aaron R Thorner; Matthew L Meyerson; Todd R Golub; Rameen Beroukhim; Gerald G Wulf; German Ott; Scott J Rodig; Stefano Monti; Donna S Neuberg; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper; Gad Getz; Margaret A Shipp
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

9.  Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

Authors:  Roland Schmitz; George W Wright; Da Wei Huang; Calvin A Johnson; James D Phelan; James Q Wang; Sandrine Roulland; Monica Kasbekar; Ryan M Young; Arthur L Shaffer; Daniel J Hodson; Wenming Xiao; Xin Yu; Yandan Yang; Hong Zhao; Weihong Xu; Xuelu Liu; Bin Zhou; Wei Du; Wing C Chan; Elaine S Jaffe; Randy D Gascoyne; Joseph M Connors; Elias Campo; Armando Lopez-Guillermo; Andreas Rosenwald; German Ott; Jan Delabie; Lisa M Rimsza; Kevin Tay Kuang Wei; Andrew D Zelenetz; John P Leonard; Nancy L Bartlett; Bao Tran; Jyoti Shetty; Yongmei Zhao; Dan R Soppet; Stefania Pittaluga; Wyndham H Wilson; Louis M Staudt
Journal:  N Engl J Med       Date:  2018-04-12       Impact factor: 91.245

10.  Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.

Authors:  Chulin Sha; Sharon Barrans; Francesco Cucco; Michael A Bentley; Matthew A Care; Thomas Cummin; Hannah Kennedy; Joe S Thompson; Rahman Uddin; Lisa Worrillow; Rebecca Chalkley; Moniek van Hoppe; Sophia Ahmed; Tom Maishman; Josh Caddy; Anna Schuh; Christoph Mamot; Catherine Burton; Reuben Tooze; Andrew Davies; Ming-Qing Du; Peter W M Johnson; David R Westhead
Journal:  J Clin Oncol       Date:  2018-12-03       Impact factor: 44.544
View more
  3 in total

1.  Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.

Authors:  Francesco Cucco; Sharon Barrans; Chulin Sha; Alexandra Clipson; Simon Crouch; Rachel Dobson; Zi Chen; Joe Sneath Thompson; Matthew A Care; Thomas Cummin; Josh Caddy; Hongxiang Liu; Anne Robinson; Anna Schuh; Jude Fitzgibbon; Daniel Painter; Alexandra Smith; Eve Roman; Reuben Tooze; Catherine Burton; Andrew J Davies; David R Westhead; Peter W M Johnson; Ming-Qing Du
Journal:  Leukemia       Date:  2019-12-16       Impact factor: 11.528

2.  A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit : A position paper from the Italian Group of Haematopathology (G.I.E.).

Authors:  Arianna Di Napoli; D Remotti; C Agostinelli; M R Ambrosio; S Ascani; A Carbone; F Facchetti; S Lazzi; L Leoncini; M Lucioni; D Novero; S Pileri; M Ponzoni; E Sabattini; C Tripodo; A Zamò; M Paulli; L Ruco
Journal:  Virchows Arch       Date:  2019-08-06       Impact factor: 4.064

Review 3.  Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas.

Authors:  Stefano A Pileri; Claudio Tripodo; Federica Melle; Giovanna Motta; Valentina Tabanelli; Stefano Fiori; Maria Carmela Vegliante; Saveria Mazzara; Sabino Ciavarella; Enrico Derenzini
Journal:  Cells       Date:  2021-03-18       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.